Ze-yang Ding, MD

Quick facts

Phase 2 pipeline

• apatinib plus camrelizumab
• Bevacizumab Biosimilar IBI305 plus sintilimab · Oncology
  Bevacizumab Biosimilar IBI305 is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while sintilimab is a PD-1 inhibitor that blocks the PD-1/PD-L1 interaction.
• Bevacizumab plus Atezolizumab · Oncology
  Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Ze-yang Ding, MD portfolio CI brief
• Ze-yang Ding, MD pipeline updates RSS

Related

• Sector hub: All tracked pharma companies